Zemprocitinib, a next-generation JAK1 inhibitor, may tame rheumatoid arthritis that does not respond to at least one biologic disease-modifying antirheumatic drug, a phase 3 clinical trial finds.

Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Key Points Interested in Aclaris Therapeutics, Inc.? Here are five stocks we like better. Aclaris Therapeutics is preparing a ...

Incyte (Nasdaq:INCY) today reports 2024 second quarter financial results, and provides a status update on the Company's clinical development portfolio. "In the ...

An intravitreal insert provides durable control of multiple retinal diseases, according to a presentation at Retina World ...

Epidemiology links AA and atopy: up to 40% of AA patients have atopic comorbidities, and concurrent AD predicts poorer response and relapse. Immune profiling shows mixed Th1/Th2/Th22 activation with ...

New immunologic and biomarker data supports the potential of ITK inhibition with soquelitinib to increase persistent Treg cells and influence ...

NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors. A fusion ...

GSK to showcase long-term outcomes and pipeline expansion with latest oncology research at ASCO and EHA: London, UK Thursday, May 28, 2026, 10:00 Hrs [IST] GSK plc will present ne ...

(Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that the independent Data ...

Investigators assessed parsaclisib for efficacy and safety in patients with myelofibrosis and suboptimal or declining response to stable ruxolitinib.